Imagine a world where a simple test could unlock life-saving treatments for brain tumor patients. That world is here, but not everyone has access to it. Recent breakthroughs in molecular and genetic testing are revolutionizing brain tumor care, offering precise diagnoses, personalized treatments, and hope for new therapies. Yet, a groundbreaking study led by Professor Kathreena Kurian at the University of Bristol and the Tessa Jowell Brain Cancer Mission reveals a stark reality: while these advancements are rapidly being adopted across the NHS, deep regional inequalities persist, leaving some patients behind.
Published in Neuro-Oncology Practice on November 13th, the study highlights the transformative potential of genomic testing, with a staggering 291% increase in whole genome sequencing (WGS) since 2021. But here’s where it gets controversial: despite this progress, access to these tests remains a postcode lottery. Some hospitals face logistical hurdles like transport delays, while others lack the basic ability to freeze tumor samples—a critical step for advanced testing. By 2024, only 71% of centers offered WGS, with Scotland and Wales lagging significantly. Patients in these regions often wait up to 150 days for results, a delay that can be the difference between life and death.
For Professor Kurian, this issue is deeply personal. Her husband, Gerard, gained precious extra time through a cutting-edge trial made possible by frozen tumor tissue and whole genome sequencing. And this is the part most people miss: something as simple as how tissue is stored can determine a patient’s access to life-saving treatments or trials. Professor Kurian’s mission is clear: to ensure every patient has the same opportunity.
The study, conducted in collaboration with 47 NHS hospitals and the Tessa Jowell Brain Cancer Mission, identifies three practical steps to achieve equity:
- Talk About It: Raise awareness that patients can decide whether their tumor tissue is used for advanced diagnosis, future treatments, and research. One conversation could save lives.
- Protect What Matters: Implement a Patient Tissue Charter to safeguard patients’ rights, ensuring every tumor sample is preserved and utilized for current and future patients.
- Make It Easy: Simplify consent processes—a single tap on the NHS App could empower patients to make informed decisions.
While the NHS’s commitment to commissioning advanced tests is commendable, the question remains: Why should access to potentially life-saving technology depend on where you live? Professor Kurian and the Tessa Jowell Brain Cancer Mission are determined to close this gap, but they can’t do it alone. What do you think? Is enough being done to ensure equitable access to these advancements? Share your thoughts in the comments below.
The journey toward universal access is far from over. With continued collaboration between charities, researchers, policymakers, and the NHS, there’s hope that every brain tumor patient, regardless of location, will one day benefit from these cutting-edge diagnostics and treatments. As Dr. Nicky Huskens, CEO of the Tessa Jowell Brain Cancer Mission, aptly puts it, ‘It is vital that this transformation benefits not just some but all patients.’ The future of brain tumor care is here—let’s make sure no one is left behind.
